Quindroit Paul, Baclet Nicolas, Gerard Erwin, Robert Laurine, Lemaitre Madleen, Gautier Sophie, Delannoy-Rousselière Chloé, Décaudin Bertrand, Vambergue Anne, Beuscart Jean-Baptiste
Univ. Lille, CHU Lille, ULR 2694-METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, F-59000 Lille, France.
Lille Catholic Hospitals, Department of Infectious Diseases, F-59000 Lille, France.
Healthcare (Basel). 2021 Nov 11;9(11):1539. doi: 10.3390/healthcare9111539.
In France, around 5% of the general population are taking drug treatments for diabetes mellitus (mainly type 2 diabetes mellitus, T2DM). Although the management of T2DM has become more complex, most of these patients are managed by their general practitioner and not a diabetologist for their antidiabetics treatments; this increases the risk of potentially inappropriate prescriptions (PIPs) of hypoglycaemic agents (HAs). Inappropriate prescribing can be assessed by approaches that are implicit (expert judgement based) or explicit (criterion based). In a mixed, multistep process, we first systematically reviewed the published definitions of PIPs for HAs in patients with T2DM. The results will be used to create the first list of explicit definitions. Next, we will complete the definitions identified in the systematic review by conducting a qualitative study with two focus groups of experts in the prescription of HAs. Lastly, a Delphi survey will then be used to build consensus among participants; the results will be validated in consensus meetings. We developed a method for determining explicit definitions of PIPs for HAs in patients with T2DM. The resulting explicit definitions could be easily integrated into computerised decision support tools for the automated detection of PIPs.
在法国，约5%的普通人群正在接受糖尿病（主要是2型糖尿病，T2DM）的药物治疗。尽管T2DM的管理变得更加复杂，但这些患者中的大多数在接受抗糖尿病治疗时是由他们的全科医生而非糖尿病专科医生管理；这增加了降糖药物（HAs）潜在不适当处方（PIPs）的风险。不适当处方可以通过隐性（基于专家判断）或显性（基于标准）的方法进行评估。在一个混合的多步骤过程中，我们首先系统地回顾了已发表的T2DM患者HAs的PIPs定义。结果将用于创建第一个显性定义列表。接下来，我们将通过与两个HAs处方专家焦点小组进行定性研究，完善系统评价中确定的定义。最后，将使用德尔菲调查在参与者之间达成共识；结果将在共识会议上得到验证。我们开发了一种确定T2DM患者HAs的PIPs显性定义的方法。由此产生的显性定义可以很容易地整合到计算机化决策支持工具中，用于自动检测PIPs。
